Ruth Ben Yakar, PhD CEO
Dr. Ben Yakar brings Biosight over 20 years of experience at various executive positions in the biotech industry, leading diverse corporate, financial, business, operational, clinical, and regulatory activities. Prior to joining Biosight, Dr. Ben Yakar served in several executive management positions in the pharmaceutical industry, including CEO of Procognia, a public biotech company, and CEO of Thrombotech, a Phase 2b biotech company she led towards acquisition. Prior to that, Dr. Ben Yakar served as the Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, where she oversaw the business aspects of all licensing deals of the Weizmann Institute of Science, and as Vice President at Gamida Cell. Dr. Ben Yakar also served as a Director at biotech companies traded on Nasdaq, Zurich, and TASE, and at Israel Advanced Technology Industries organization, and is a member of 8400 Cohort 1. Dr. Ben Yakar holds a PhD Cum Laude in molecular cell biology from the Weizmann Institute of Science.
Roy Golan, CPA, LLM Executive VP & CFO
Mr. Golan is a registered CPA with a broad experience in aspects of Nasdaq, IPOs and M&As. Prior to joining BioSight, Mr. Golan served in several financial management positions in the biotech industry, including as the CFO of Neuroderm, where he had a pivotal role in their successful Nasdaq IPO, two Follow-On Offerings, and Neuroderm's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of US$1.1 billion. Mr. Golan started his career at PriceWaterhouseCoopers (PWC). Mr. Golan is a registered CPA, holds a B.A. in Accounting and Business from the Israeli College of Management School of Business and an LL.M. in Law from Bar Ilan University.
Liat Flaishon, MD, PhD VP Medical Affairs
Dr. Flaishon brings 20 years of experience in managing clinical trials in the pharmaceutical industry and as a board-certified internal medicine physician. Prior to joining BioSight, Dr. Flaishon served in several positions in the industry, including VP Clinical Affairs at Intec Pharma, a Phase 3 biotech company, where she led early and advanced clinical projects, and a Director of Drug Safety Risk Management Plans in the global Pharmacovigilance Department at Teva Pharmaceuticals, where she accompanied products from early development stages to commercialization. Dr. Flaishon served as an internal medicine physician at the Tel-Aviv Sourasky Medical Center. Dr. Flaishon holds a medical degree from Tel-Aviv University and a PhD degree in Immunology from the Weizmann Institute of Science.
Shoshi Tessler, PhD VP Research & Development
Dr. Tessler brings to BioSight over 20 years of experience in the pharmaceutical industry, leading a broad range of drug development projects and activities, from lead-stage to Phase 3 and registration. Dr. Tessler previously served as the VP R&D of Enzymotec and as a Senior Director Project Champion at the Innovative R&D in Teva Pharmaceuticals, leading diverse drug development projects throughout their life cycle. Her experience and responsibilities included management of all aspects of drug development, including CMC, pharmacology, toxicology, mechanism of action, regulatory affairs, clinical development, and intellectual property. Dr. Tessler received her PhD from the Technion, Haifa, Israel in the area of growth factors and cancer development, followed by a post-doctoral fellowship at the Babraham Institute, Cambridge, UK.
Margarita Shumilov, B Pharm, PhD Director, CMC & QA
Dr. Shumilov brings vast experience in various CMC aspects of drug development & commercialization. Prior to joining Biosight, Dr. Shumilov served as a Team Leader in the Pharmaceutical Operations group and a CMC Projects Leader at the Innovative R&D division of Teva Pharmaceuticals Industries, where she successfully led the CMC aspects of Teva’s products for FDA approval. Dr. Shumilov specializes in the development of various sterile and solid dosage forms and drug-device combination products, from early preclinical stages to commercialization. In addition, Dr. Shumilov has an extensive experience in the scale-up, optimization, and validation of the manufacturing processes. Dr. Shumilov is a licensed pharmacist and holds a PhD in Pharmaceutical Sciences from the Hebrew University of Jerusalem.
Yaron Ramati, PhD Director, Regulatory Affairs
Dr. Ramati brings 15 years of accumulated experience in regulation of novel biotechnological therapies, from early phases to late-stage clinical development, extensive experience in initiation of clinical development negotiations, and agreements with regulators on quality and late-stage clinical development. Dr. Ramati served as responsible of regulatory affairs in several companies, including Director of Regulatory Affairs, and Senior Director of Clinical Innovation in Pluristem Therapeutics, a biotechnology company developing allogeneic cell therapy. Dr. Ramati was involved in the pipeline development for several biotechnology products in clinical development stage, and functioned as company representative in discussions over clinical development and quality matters with FDA, EMA, and PMDA, as well as leading the discussion with several health technology assessment bodies. Dr. Ramati holds a Bachelor degree from the Technion School of Medicine, a Master degree in Neurobiology from the Technion, a Master degree in philosophy of science from the University of Haifa, and a Ph.D. in philosophy of science from the London School of Economics.